Peptide United

Specimen index

Peptide Database

8 peptides filtered results

Filtered by:PureRawz

PT-141

Approved

Bremelanotide · Vyleesi

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist, FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through MC3R and MC4R receptors in the hypothalamus to initiate sexual arousal, making it effective for psychological as well as physiological sexual dysfunction. Research also explores applications in male erectile dysfunction.

Sexual Health
Available fromBehemoth LabzPureRawz

Selank

Approved

Selanc · TP-7

Selank is a synthetic heptapeptide analog of tuftsin developed by the Russian Institute of Molecular Genetics. Approved in Russia for anxiety and cognitive disorders, it exhibits anxiolytic effects comparable to benzodiazepines without sedation or dependence. Research shows it modulates GABA, serotonin, and dopamine systems, enhances BDNF expression, and improves memory consolidation and learning.

C₃₃H₅₇N₁₁O₉ · 751.87 Da

Cognitive EnhancementImmune Support
Available fromBC9PureRawz

Semaglutide

Approved

Ozempic · Wegovy

Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and obesity (Wegovy). By mimicking the incretin hormone GLP-1, it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central hypothalamic pathways. Landmark trials demonstrate up to 15–17% body weight reduction and significant cardiovascular mortality benefit.

GLP-1 & Metabolic HormonesFat Loss & MetabolicCardiovascular
Available fromPureRawz

Semax

Approved

MEHFPGP · Pro8-Gly9-Pro10-ACTH(4–10)

Semax is a synthetic heptapeptide analog of ACTH(4-7) developed in Russia, where it is approved for stroke, TBI, peptic ulcers, and cognitive enhancement. It upregulates BDNF and its receptor TrkB, promotes dopamine and serotonin turnover, and has demonstrated neuroprotective effects in ischemia models. Research highlights improvements in attention, memory, and recovery from neurological injury.

Cognitive EnhancementNeuroprotection
Available fromBC9PureRawz

Sermorelin

Approved

GHRH(1-29) · GRF 1-29 NH2

Sermorelin is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary to produce and secrete growth hormone in a pulsatile, physiologic manner. FDA-approved for GH deficiency in children, it is extensively researched in adults for body composition, sleep quality, and age-related GH decline.

C₁₄₉H₂₄₆N₄₄O₄₂S · 3357.88 Da

Growth Hormone AxisAnti-Aging & Longevity
Available fromBehemoth LabzPureRawz

Tesamorelin

Approved

Egrifta · TH9507

Tesamorelin is a stabilized synthetic GHRH analog FDA-approved for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It stimulates pulsatile GH secretion while preserving natural feedback regulation. Research demonstrates significant visceral adipose tissue reduction, improved lipid profiles, and cognitive benefits, making it a key study compound for metabolic dysfunction.

Growth Hormone AxisFat Loss & Metabolic
Available fromBehemoth LabzPureRawz

Thymosin Alpha-1

Approved

Thymalfasin · Tα1

Thymosin Alpha-1 is a naturally occurring 28-amino-acid peptide derived from thymosin fraction 5 of the thymus gland. Approved in over 35 countries for hepatitis B, hepatitis C, and as an immune adjuvant in cancer therapy, it enhances T-cell maturation, dendritic cell function, and NK cell activity. Research continues to expand into sepsis, COVID-19, autoimmune conditions, and vaccine response enhancement.

C₁₂₉H₂₁₅N₃₃O₅₅ · 3108.29 Da

Immune SupportAnti-Aging & Longevity
Available fromBehemoth LabzPureRawz

Tirzepatide

Approved

Mounjaro · Zepbound

Tirzepatide is the first dual GIP/GLP-1 receptor agonist, approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). By co-activating both incretin receptors, it achieves superior glycemic control and weight reduction compared to GLP-1 monotherapy — SURMOUNT trials showed up to 22.5% body weight reduction. It represents a new class of metabolic peptide therapeutics with broad cardiovascular and metabolic benefits.

GLP-1 & Metabolic HormonesFat Loss & Metabolic
Available fromPureRawz